Drug intelligence / Profile preview

MSP1(42)-FVO + MSP1(42)-3D7

Development stage: Phase 1
Lead developer: Malaria Vaccine Development Branch
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MSP1(42)-FVO + MSP1(42)-3D7 is a combination vaccine targeting blood-stage Plasmodium falciparum parasites. It consists of two recombinant proteins representing the C-terminal 42-kDa region of merozoite surface protein 1 (MSP1(42)) corresponding to the two allelic forms present in FVO and 3D7 P. falciparum lines. These proteins are expressed in Escherichia coli, refolded, purified, and formulated on Alhydrogel (aluminum hydroxide). The vaccine aims to induce immune responses that cover the major antigenic polymorphisms of MSP1, a leading blood-stage malaria vaccine candidate.

Other names: MSP1(42)-C1

Targets

MSP1 (Merozoite surface protein 1)

Beyond the preview

Go deeper on MSP1(42)-FVO + MSP1(42)-3D7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSP1(42)-FVO + MSP1(42)-3D7.

Explore the full profile